Eliphos

Hyperphosphataemia, Communicable Diseases, Dialysis therapy + 4 more

Treatment

3 FDA approvals

3 Active Studies for Eliphos

What is Eliphos

Calcium acetate

The Generic name of this drug

Treatment Summary

Calcium acetate is a compound made of calcium and acetic acid. It is also known as the acetate of lime and usually comes in the form of a monohydrate, which is very absorbent.

ProcalAmine

is the brand name

image of different drug pills on a surface

Eliphos Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

ProcalAmine

Calcium acetate

1982

77

Approved as Treatment by the FDA

Calcium acetate, otherwise known as ProcalAmine, is approved by the FDA for 3 uses which include Kidney Failure, Chronic and End-stage Renal Failure (ESRF) .

Kidney Failure, Chronic

Helps manage End-stage Renal Failure (ESRF)

End-stage Renal Failure (ESRF)

Helps manage End-stage Renal Failure (ESRF)

Hyperphosphataemia

Helps manage Hyperphosphataemia

Effectiveness

How Eliphos Affects Patients

People with advanced kidney problems (creatinine clearance less than 30 ml/min) often have too much phosphate in the body, which can lead to an increase in hormones related to bone and tissue damage. This can be managed with dietary changes and dialysis, but it is not always enough. To reduce the amount of phosphate taken in from meals, phosphate binders such as calcium acetate can be taken. This binds to dietary phosphate to make it insoluble, so it is eliminated from the body in the feces. The goal of treatment with phosphate binders is usually to keep the phosphate levels in the body below 6.0 mg/

How Eliphos works in the body

Calcium acetate binds to the phosphate in food, so it can't be absorbed by your body. Instead, it is passed out of your body without being used.

When to interrupt dosage

The measure of Eliphos is contingent upon the determined disorder, including Kidney, Hyperphosphataemia and Kidney Failure, Chronic. The amount of dosage additionally shifts as per the method of delivery (e.g. Intravenous or Topical) included in the table beneath.

Condition

Dosage

Administration

Hyperphosphataemia

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

Kidney

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

high phosphate levels

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

Astringent

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

Communicable Diseases

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

Dialysis therapy

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

Kidney Failure, Chronic

667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Injection - Intravenous, Injection, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Intravenous, Tablet, coated, Solution - Topical, Tablet, coated - Oral

Warnings

Eliphos has two contraindications, thus it should not be utilized for the conditions given in the accompanying table.

Eliphos Contraindications

Condition

Risk Level

Notes

Hypercalcemia

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Eliphos.

Common Eliphos Drug Interactions

Drug Name

Risk Level

Description

Technetium Tc-99m oxidronate

Major

Calcium acetate may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.

Dobutamine

Minor

The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium acetate.

3-Aza-2,3-Dihydrogeranyl Diphosphate

Moderate

Calcium acetate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Acebutolol

Moderate

The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium acetate.

Acetyldigitoxin

Moderate

Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.

Eliphos Toxicity & Overdose Risk

The toxic dose of the drug in rats is 4280mg/kg. Mild signs of an overdose include constipation, loss of appetite, nausea, and vomiting. More severe symptoms include confusion, unconsciousness, and difficulty speaking.

image of a doctor in a lab doing drug, clinical research

Eliphos Novel Uses: Which Conditions Have a Clinical Trial Featuring Eliphos?

Currently, 5 active studies are underway to assess the effectiveness of Eliphos in managing Kidney conditions, elevated phosphate levels and Hyperphosphataemia.

Condition

Clinical Trials

Trial Phases

high phosphate levels

0 Actively Recruiting

Kidney Failure, Chronic

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Hyperphosphataemia

0 Actively Recruiting

Dialysis therapy

3 Actively Recruiting

Not Applicable, Phase 3, Phase 4

Astringent

0 Actively Recruiting

Kidney

0 Actively Recruiting

Eliphos Reviews: What are patients saying about Eliphos?

5

Patient Review

5/20/2009

Eliphos for Renal Osteodystrophy with Hyperphosphatemia

This treatment lowered my phosphorus levels quickly and effectively. It was also more affordable than other options on the market.

Patient Q&A Section about eliphos

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What drug class is calcium acetate?

"Calcium acetate is a medication that is used to bind phosphorus in the diet and prevent it from being absorbed into the blood stream."

Answered by AI

What is calcium acetate used for?

"Calcium acetate is a medication used to treat hyperphosphatemia (too much phosphate in the blood) in patients with end stage kidney disease who are on dialysis. Calcium acetate works by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed."

Answered by AI

What is PhosLo used for?

"Phoslo is used as a calcium supplement to control phosphate levels in the blood for patients with severe kidney disease who are on dialysis."

Answered by AI

What is Eliphos used for?

"Eliphos is a phosphate binder that is indicated to help reduce serum phosphorus levels in patients with end stage renal disease. The recommended initial dose for adult dialysis patients is 2 tablets with each meal."

Answered by AI

Clinical Trials for Eliphos

Image of Rocky Mountain Kidney Care - Lone Tree in Lone Tree, United States.

AP301 for High Phosphate Levels

Any Age
All Sexes
Lone Tree, CO

The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.

Phase 3
Recruiting

Rocky Mountain Kidney Care - Lone Tree (+18 Sites)

Alebund Pharmaceuticals